JP2019530640A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019530640A5 JP2019530640A5 JP2019502573A JP2019502573A JP2019530640A5 JP 2019530640 A5 JP2019530640 A5 JP 2019530640A5 JP 2019502573 A JP2019502573 A JP 2019502573A JP 2019502573 A JP2019502573 A JP 2019502573A JP 2019530640 A5 JP2019530640 A5 JP 2019530640A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- sequence number
- binding molecule
- binding
- multimer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims description 43
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims description 41
- 210000004027 cell Anatomy 0.000 claims description 27
- 239000012634 fragment Substances 0.000 claims description 23
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 21
- 239000000427 antigen Substances 0.000 claims description 18
- 102000036639 antigens Human genes 0.000 claims description 18
- 108091007433 antigens Proteins 0.000 claims description 18
- 108091033319 polynucleotide Proteins 0.000 claims description 14
- 102000040430 polynucleotide Human genes 0.000 claims description 14
- 239000002157 polynucleotide Substances 0.000 claims description 14
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 12
- 230000001404 mediated effect Effects 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 9
- 206010028980 Neoplasm Diseases 0.000 claims description 8
- 230000011664 signaling Effects 0.000 claims description 8
- 101000840258 Homo sapiens Immunoglobulin J chain Proteins 0.000 claims description 6
- 102100029571 Immunoglobulin J chain Human genes 0.000 claims description 6
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 6
- 229920001184 polypeptide Polymers 0.000 claims description 6
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 6
- 210000003162 effector t lymphocyte Anatomy 0.000 claims description 5
- 230000001939 inductive effect Effects 0.000 claims description 5
- 239000000178 monomer Substances 0.000 claims description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 5
- 210000003289 regulatory T cell Anatomy 0.000 claims description 5
- 230000004044 response Effects 0.000 claims description 5
- 230000002476 tumorcidal effect Effects 0.000 claims description 5
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims description 4
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims description 4
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 claims description 4
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 claims description 4
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 230000000977 initiatory effect Effects 0.000 claims description 4
- 238000006467 substitution reaction Methods 0.000 claims description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 3
- 238000004132 cross linking Methods 0.000 claims description 3
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 150000007523 nucleic acids Chemical group 0.000 claims description 3
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 2
- 102000004127 Cytokines Human genes 0.000 claims description 2
- 108090000695 Cytokines Proteins 0.000 claims description 2
- 230000003213 activating effect Effects 0.000 claims description 2
- 230000005809 anti-tumor immunity Effects 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 230000002757 inflammatory effect Effects 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 230000035755 proliferation Effects 0.000 claims description 2
- 210000004881 tumor cell Anatomy 0.000 claims description 2
- 230000005909 tumor killing Effects 0.000 claims description 2
- 230000008878 coupling Effects 0.000 claims 1
- 238000010168 coupling process Methods 0.000 claims 1
- 238000005859 coupling reaction Methods 0.000 claims 1
- 101001055311 Equus asinus Immunoglobulin heavy constant alpha Proteins 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102400001107 Secretory component Human genes 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662364763P | 2016-07-20 | 2016-07-20 | |
| US62/364,763 | 2016-07-20 | ||
| PCT/US2017/043165 WO2018017888A1 (en) | 2016-07-20 | 2017-07-20 | Multimeric ox40 binding molecules and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019530640A JP2019530640A (ja) | 2019-10-24 |
| JP2019530640A5 true JP2019530640A5 (enExample) | 2020-08-13 |
Family
ID=60996094
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019502573A Withdrawn JP2019530640A (ja) | 2016-07-20 | 2017-07-20 | 多量体ｏｘ４０結合分子及びその使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20190330374A1 (enExample) |
| EP (1) | EP3487533A4 (enExample) |
| JP (1) | JP2019530640A (enExample) |
| CN (1) | CN109562165A (enExample) |
| AU (1) | AU2017298483A1 (enExample) |
| CA (1) | CA3030647A1 (enExample) |
| IL (1) | IL263799A (enExample) |
| MX (1) | MX2019000796A (enExample) |
| WO (1) | WO2018017888A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105722855B (zh) | 2013-09-05 | 2021-04-23 | Igm生物科学股份有限公司 | 恒定链经修饰的双特异性五价和六价Ig-M抗体 |
| KR102378289B1 (ko) | 2014-02-10 | 2022-03-23 | 아이쥐엠 바이오사이언스 인코포레이티드 | IgA 다중-특이적 결합 분자 |
| CN112759650B (zh) | 2014-04-03 | 2024-10-01 | Igm生物科学股份有限公司 | 修饰的j链 |
| CA2972990A1 (en) | 2015-01-20 | 2016-07-28 | Beatrice Tien-Yi WANG | Tumor necrosis factor (tnf) superfamily receptor binding molecules and uses thereof |
| NZ762365A (en) | 2015-03-04 | 2024-11-29 | Igm Biosciences Inc | Cd20 binding molecules and uses thereof |
| WO2016154593A1 (en) | 2015-03-25 | 2016-09-29 | Igm Biosciences, Inc. | Multi-valent hepatitis b virus antigen binding molecules and uses thereof |
| CN107847591B (zh) | 2015-04-17 | 2023-07-28 | Igm生物科学股份有限公司 | 多价人免疫缺陷病毒抗原结合分子及其应用 |
| WO2017059387A1 (en) | 2015-09-30 | 2017-04-06 | Igm Biosciences, Inc. | Binding molecules with modified j-chain |
| PL3355913T3 (pl) | 2015-09-30 | 2025-02-17 | Igm Biosciences, Inc. | Cząsteczki wiążące ze zmodyfikowanym łańcuchem j |
| DK3455257T3 (da) | 2016-05-09 | 2021-11-01 | Igm Biosciences Inc | Anti-pd-l1-antistoffer |
| KR102696143B1 (ko) | 2017-04-07 | 2024-08-21 | 아이쥐엠 바이오사이언스 인코포레이티드 | 보체-의존성 세포용해 효과기 기능의 조정을 위한 변형된 인간 IgM 불변 영역 |
| MX2020009069A (es) | 2018-03-01 | 2020-10-08 | Igm Biosciences Inc | Mutaciones de fc de igm y de la cadena j que afectan la semivida de igm en suero. |
| WO2020063668A1 (zh) * | 2018-09-25 | 2020-04-02 | 信达生物制药(苏州)有限公司 | 包含抗ox40抗体的制剂、其制备方法及其用途 |
| EP3870223A4 (en) * | 2018-10-23 | 2022-08-24 | IGM Biosciences, Inc. | MULTIVALENT IGM AND IGA-FC BASED BINDING MOLECULES |
| CN110172090B (zh) * | 2019-06-03 | 2020-04-03 | 中山标佳生物科技有限公司 | Cd134单克隆抗体及其制备方法和癌症治疗中的应用 |
| CA3147291A1 (en) | 2019-08-15 | 2021-02-18 | Igm Biosciences, Inc. | Immunostimulatory multimeric binding molecules |
| EP4139362A2 (en) | 2020-04-22 | 2023-03-01 | IGM Biosciences Inc. | Pd-1 agonist multimeric binding molecules |
| CN112957475B (zh) * | 2021-02-04 | 2022-07-22 | 李文峰 | 一种预防和或治疗肿瘤的组合物及应用 |
| US20220332837A1 (en) * | 2021-04-08 | 2022-10-20 | Colorado State University Research Foundation | Methods and compositions for ox40 activation in treatment of canine cancer |
| WO2025160083A1 (en) * | 2024-01-22 | 2025-07-31 | Onko-Innate Pty Ltd | Targeted low potency il-12 fc fusion proteins and uses thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201116092D0 (en) * | 2011-09-16 | 2011-11-02 | Bioceros B V | Antibodies and uses thereof |
| US9382319B2 (en) * | 2011-09-26 | 2016-07-05 | Jn Biosciences Llc | Hybrid constant regions |
| EP2812022B1 (en) * | 2012-02-06 | 2019-06-26 | Providence Health & Services - Oregon | Method of monitoring cancer treatment using ox40 agonists |
| CA2943834A1 (en) * | 2014-03-31 | 2015-10-08 | Genentech, Inc. | Combination therapy comprising anti-angiogenesis agents and ox40 binding agonists |
| TW201619200A (zh) * | 2014-10-10 | 2016-06-01 | 麥迪紐有限責任公司 | 人類化抗－ｏｘ４０抗體及其用途 |
| RU2022106508A (ru) * | 2016-01-11 | 2022-04-05 | Инхибркс, Инк. | Поливалентные и полиспецифические ох40-связывающие слитые белки |
-
2017
- 2017-07-20 MX MX2019000796A patent/MX2019000796A/es unknown
- 2017-07-20 CN CN201780044931.3A patent/CN109562165A/zh active Pending
- 2017-07-20 US US16/317,814 patent/US20190330374A1/en not_active Abandoned
- 2017-07-20 EP EP17831908.3A patent/EP3487533A4/en not_active Withdrawn
- 2017-07-20 JP JP2019502573A patent/JP2019530640A/ja not_active Withdrawn
- 2017-07-20 CA CA3030647A patent/CA3030647A1/en not_active Abandoned
- 2017-07-20 WO PCT/US2017/043165 patent/WO2018017888A1/en not_active Ceased
- 2017-07-20 AU AU2017298483A patent/AU2017298483A1/en not_active Abandoned
-
2018
- 2018-12-18 IL IL263799A patent/IL263799A/en unknown
-
2022
- 2022-02-17 US US17/673,864 patent/US20220169751A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019530640A5 (enExample) | ||
| JP2019528683A5 (enExample) | ||
| JP2022177090A5 (enExample) | ||
| JP7551693B2 (ja) | ＮＫｐ４６結合タンパク質の可変領域 | |
| CN109071664B (zh) | 新型抗-SIRPa抗体及其治疗应用 | |
| JP2018503401A5 (enExample) | ||
| JP2021006044A (ja) | 腫瘍壊死因子 （ｔｎｆ） スーパーファミリー受容体結合分子およびその使用 | |
| CN113874399B (zh) | 抗ror1/抗cd3双特异性结合分子 | |
| CA2983706C (en) | Combination of a cd30xcd16 antibody with a pd-1 antagonist for therapy | |
| JP2016507555A5 (enExample) | ||
| JP2018512863A5 (enExample) | ||
| RU2019134352A (ru) | Новые биспецифические антигенсвязывающие молекулы, обладающие способностью специфически связываться с cd40 и fap | |
| JP2019502676A5 (enExample) | ||
| JP2020529835A5 (enExample) | ||
| JP2020536573A5 (enExample) | ||
| JP2020528768A5 (enExample) | ||
| RU2018143439A (ru) | Антигенсвязывающие молекулы, содержащие тримерный лиганд семейства tnf и pd1-связывающий фрагмент | |
| JP2018508214A5 (enExample) | ||
| JP2020501531A5 (enExample) | ||
| JP2018527919A5 (enExample) | ||
| JP2019531084A5 (enExample) | ||
| CA2896548A1 (en) | Multivalent binding protein compositions | |
| JP7489468B2 (ja) | 二重特異性融合タンパク質及びその応用 | |
| CA3030647A1 (en) | Multimeric ox40 binding molecules and uses thereof | |
| WO2019073080A1 (en) | ANTI-SIRPA MODIFIED ANTIBODIES AND USES THEREOF |